Advances of anaplastic lymphoma kinase in non-small cell lung cancer / 国际肿瘤学杂志

ABSTRACT

Targeted therapy is the most prospective part of the research related to the treatment of non-small cell lung cancer(NSCLC). After epidermal growth factor receptor(EGFR),anaplastic lymphoma kinase (ALK)gene is expected to become a new target in the treatment of NSCLC. Moreover,several related resear-ches suggest that ALK inhibitor(crizotinib)is effective for treatment of ALK-rearranged NSCLC. Therefore,it is important to review the detection method of ALK gene,clinicopathologic features and the research progress of ALK inhibitor for the individual treatment of NSCLC.